Novel Targeted Therapies for Inflammatory Bowel Disease

Trends in Pharmacological Sciences

Volumn 38, Issue 2, 2017, Pages 127-142

  Coskun, Mehmet ^a,b   Vermeire, Severine ^c   Nielsen, Ole Haagen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

antisense therapy; biologics; Crohn's disease; leukocyte trafficking; small molecules; ulcerative colitis

Indexed keywords

ABRILUMAB; AJM 300; AMISELIMOD; BI 655066; BRAZIKUMAB; CREATINE KINASE; ETRASIMOD; ETROLIZUMAB; FILGOTINIB; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; JANUS KINASE; LAQUINIMOD; MERCAPTOPURINE; MONGERSEN; MONOCLONAL ANTIBODY; NATALIZUMAB; OZANIMOD; PEFICITINIB; PF 00547659; PF 04236921; PLACEBO; SMAD7 PROTEIN; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB; VEDOLIZUMAB; AJM300; ANTISENSE OLIGONUCLEOTIDE; INDAN DERIVATIVE; JANUS KINASE 1; OXADIAZOLE DERIVATIVE; PHENYLALANINE; QUINAZOLINONE DERIVATIVE; QUINOLONE DERIVATIVE;

ABSCESS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLOSTRIDIUM INFECTION; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM PERFORATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; GASTROINTESTINAL ABSCESS; GASTROINTESTINAL DISEASE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOPATHOGENESIS; INFECTION; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE MIGRATION; LISTERIA MENINGITIS; LOADING DRUG DOSE; OPPORTUNISTIC INFECTION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; SEPSIS; SIDE EFFECT; TUBERCULOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; INFLAMMATORY BOWEL DISEASES;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INDANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-23; INTERLEUKIN-6; JANUS KINASE 1; OLIGONUCLEOTIDES, ANTISENSE; OXADIAZOLES; PHENYLALANINE; PRECISION MEDICINE; QUINAZOLINONES; QUINOLONES; SMAD7 PROTEIN;

EID: 85007487754     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.10.014     Document Type: Review

References (102)

1. 1 Ordas, I., et al. Ulcerative colitis. Lancet 380 (2012), 1606–1619.
2. 2 Baumgart, D.C., Sandborn, W.J., Crohn's disease. Lancet 380 (2012), 1590–1605.
3. 3 Molodecky, N.A., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142 (2012), 46–54.
4. 4 Hoivik, M.L., et al. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut 62 (2013), 368–375.
5. 5 Burisch, J., et al. The burden of inflammatory bowel disease in Europe. J. Crohns. Colitis 7 (2013), 322–337.
6. 6 Kostic, A.D., et al. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146 (2014), 1489–1499.
7. 7 Neurath, M.F., Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14 (2014), 329–342.
8. 8 de Souza, H.S., Fiocchi, C., Immunopathogenesis of IBD: current state of the art. Nat. Rev. Gastroenterol. Hepatol. 13 (2016), 13–27.
9. 9 Cammarota, G., et al. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol. Ther. 149 (2015), 191–212.
10. 10 Atreya, R., Neurath, M.F., IBD pathogenesis in 2014: molecular pathways controlling barrier function in IBD. Nat. Rev. Gastroenterol. Hepatol. 12 (2015), 67–68.
11. 11 Gerlach, K., et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat. Immunol. 15 (2014), 676–686.
12. 12 Zundler, S., et al. Blockade of alphaEbeta7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. Gut., 2016, 10.1136/gutjnl-2016-312439 Published online August 19, 2016.
13. 13 Habtezion, A., et al. Leukocyte trafficking to the small intestine and colon. Gastroenterology 150 (2016), 340–354.
14. 14 Binion, D.G., et al. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 112 (1997), 1895–1907.
15. 15 Danese, S., Panes, J., Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology 147 (2014), 981–989.
16. 16 Coskun, M., et al. Pharmacology and optimization of thiopurines and methotrexate in inflammatory bowel disease. Clin. Pharmacokinet. 55 (2016), 257–274.
17. 17 Nielsen, O.H., et al. The role and advances of immunomodulator therapy for inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 9 (2015), 177–189.
18. 18 Nielsen, O.H., Ainsworth, M.A., Tumor necrosis factor inhibitors for inflammatory bowel disease. N. Engl. J. Med. 369 (2013), 754–762.
19. 19 Danese, S., et al. Biologic agents for IBD: practical insights. Nat. Rev. Gastroenterol. Hepatol. 12 (2015), 537–545.
20. 20 Olesen, C.M., et al. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol. Ther. 159 (2016), 110–119.
21. 21 Torres, J., et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology 149 (2015), 1716–1730.
22. 22 Gisbert, J.P., et al. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am. J. Gastroenterol 111 (2016), 632–647.
23. 23 Frolkis, A.D., et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 145 (2013), 996–1006.
24. 24 Roda, G., et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin. Transl. Gastroenterol., 7, 2016, e135.
25. 25 Ho, L.J., et al. Biological effects of interleukin-6: clinical applications in autoimmune diseases and cancers. Biochem. Pharmacol. 97 (2015), 16–26.
26. 26 Ataie-Kachoie, P., et al. Gene of the month: interleukin 6 (IL-6). J. Clin. Pathol. 67 (2014), 932–937.
27. 27 Calabrese, L.H., Rose-John, S., IL-6 biology: implications for clinical targeting in rheumatic disease. Nat. Rev. Rheumatol. 10 (2014), 720–727.
28. 28 Hunter, C.A., Jones, S.A., IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16 (2015), 448–457.
29. 29 Heinrich, P.C., et al. Interleukin-6 and the acute phase response. Biochem. J. 265 (1990), 621–636.
30. 30 Isaacs, K.L., et al. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 103 (1992), 1587–1595.
31. 31 Reinecker, H.C., et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. 94 (1993), 174–181.
32. 32 Gross, V., et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 102 (1992), 514–519.
33. 33 Holub, M.C., et al. Increased interleukin-6 levels, interleukin-6 receptor and gp130 expression in peripheral lymphocytes of patients with inflammatory bowel disease. Scand. J. Gastroenterol. 228:Suppl. (1998), 47–50.
34. 34 Hosokawa, T., et al. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J. Gastroenterol. Hepatol. 14 (1999), 987–996.
35. 35 Ito, H., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126 (2004), 989–996.
36. 36 Danese, S., et al. Results of Andante, a randomized clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn's disease who are anti-TNF inadequate responders. Gastroenterology, 150(Suppl. 1), 2016, S155.
37. 37 Teng, M.W., et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 21 (2015), 719–729.
38. 38 Parham, C., et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168 (2002), 5699–5708.
39. 39 Pedersen, J., et al. Inflammatory pathways of importance for management of inflammatory bowel disease. World J. Gastroenterol. 20 (2014), 64–77.
40. 40 Jostins, L., et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491 (2012), 119–124.
41. 41 Duerr, R.H., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006), 1461–1463.
42. 42 Momozawa, Y., et al. Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat. Genet. 43 (2011), 43–47.
43. 43 Sandborn, W.J., et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135 (2008), 1130–1141.
44. 44 Sandborn, W.J., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367 (2012), 1519–1528.
45. 45 Sandborn, W., et al. A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12/23P40 mAb, in moderate-severe Crohn's disease refractory to anti-TNFalpha: UNITI-1. Inflamm. Bowel. Dis., 22(Suppl. 1), 2016, S1.
46. 46 Rutgeerts, P., et al. A multicentre, double-blind, placebo-controlled phase 3 study of ustekinumab, a human interleukins-12/23p40 mAb, in moderate-severe Crohn's disease refractory to anti-tumour necrosis factor A: UNITI-1. J. Crohns. Colitis 10:Suppl. 1 (2016), S11–S12.
47. 47 Feagan, B., et al. A multicenter, double-blind, placebo (PBO)-controlled PH3 study of ustekinumab (UST), a human monoclonal antibody to IL-12/23p40, in patients with moderately-severely active Crohn's disease (CD) who are naïve or not refractory to anti-tnf: UNITI-2. Gut 65 (2016), A6–A7.
48. 48 Sandborn, W., et al. A Phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate–severe Crohn's disease patients: results from IM-UNITI. Gastroenterology 150:Suppl. 1 (2016), S157–S158.
49. 49 Feagan, B.G., et al. Efficacy and safety of induction therapy with the selective IL-23 inhibitor BI 655066, in patients with moderate-to-severe Crohn's disease: results of a randomized, double-Blind, placebo-controlled phase II study. Gastroenterology, 150(Suppl. 1), 2016, S1266.
50. 50 Coskun, M., et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol. Res. 76C (2013), 1–8.
51. 51 Danese, S., et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am. J. Physiol. Gastrointest. Liver Physiol. 310 (2016), G155–G162.
52. 52 Sandborn, W.J., et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367 (2012), 616–624.
53. 53 Sandborn, W.J., et al. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials. Gastroenterology, 150(Suppl. 1), 2016, S157.
54. 54 Sands, B., et al. Tofacitinib has induction efficacy in moderately to severely active ulcerative colitis, regardless of prior TNF inhibitor therapy. Am. J Gastroenterol., 111(Suppl. 1), 2016, S261.
55. 55 Sandborn, W.J., et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin. Gastroenterol. Hepatol. 12 (2014), 1485–1493.
56. 56 Panes, J., et al. OP021 Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate-to-severe Crohns disease: results of a Phase 2b randomised placebo-controlled trial. J. Crohns. Colitis 10:Suppl. 1 (2016), S17–S18.
57. 57 D'Haens, G., et al. Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate to severe Crohn's disease: results of a phase 2b randomized placebo-controlled trial. Gastroenterology, 150(Suppl. 1), 2016, S183.
58. 58 Van, R.L., et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J. Immunol. 191 (2013), 3568–3577.
59. 59 Vermeire, S., et al. Filgotinib (GLPG0634), an oral JAK1 selective inhibitor, induces clinical remission in patients with moderate-to-severe Crohn's disease: results from the phase 2 FITZROY study interim analysis. Gastroenterology, 150(Suppl. 1), 2016, S1267.
60. 60 Di, S.A., et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 58 (2009), 777–789.
61. 61 Marafini, I., et al. TGF-beta signaling manipulation as potential therapy for IBD. Curr. Drug Targets. 14 (2013), 1400–1404.
62. 62 Marafini, I., et al. Antisense approach to inflammatory bowel disease: prospects and challenges. Drugs 75 (2015), 723–730.
63. 63 Monteleone, G., et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108 (2001), 601–609.
64. 64 Monteleone, G., et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N. Engl. J. Med. 372 (2015), 1104–1113.
65. 65 Monteleone, G., et al. Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease. Aliment. Pharmacol. Ther. 43 (2016), 717–724.
66. 66 Brunmark, C., et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 130 (2002), 163–172.
67. 67 Zou, L.P., et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 42 (2002), 731–739.
68. 68 D'Haens, G., et al. A phase II study of laquinimod in Crohn's disease. Gut 64 (2015), 1227–1235.
69. 69 Sandborn, W.J., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353 (2005), 1912–1925.
70. 70 Targan, S.R., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132 (2007), 1672–1683.
71. 71 Van, A.G., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353 (2005), 362–368.
72. 72 Bloomgren, G., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J Med. 366 (2012), 1870–1880.
73. 73 Yoshimura, N., et al. Safety and efficacy of AJM300, an oral antagonist of alpha4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology 149 (2015), 1775–1783.
74. 74 Feagan, B.G., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369 (2013), 699–710.
75. 75 Sandborn, W.J., et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 369 (2013), 711–721.
76. 76 Sands, B.E., et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 147 (2014), 618–627.
77. 77 Feagan, B.G., et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to TNF antagonists. Clin. Gastroenterol. Hepatol., 2016, 10.1016/j.cgh.2016.08.044 Published online September 14, 2016.
78. 78 Colombel, J.F., et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut, 2016, 10.1136/gutjnl-2015-311079 Published online February 18, 2016.
79. 79 Vermeire, S., et al. Long-term efficacy of vedolizumab for Crohn's disease. J. Crohns Colitis., 2016, 10.1093/ecco-jcc/jjw176 Published online September 28, 2016.
80. 80 Loftus, E.V. Jr., et al. Long-term efficacy of vedolizumab for ulcerative colitis. J. Crohns Colitis., 2016, 10.1093/ecco-jcc/jjw177 Published online September 28, 2016.
81. 81 Pan, W.J., et al. Clinical pharmacology of AMG 181, a gut-specific human anti-alpha4beta7 monoclonal antibody, for treating inflammatory bowel diseases. Br. J. Clin. Pharmacol. 78 (2014), 1315–1333.
82. 82 Cepek, K.L., et al. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J. Immunol. 150 (1993), 3459–3470.
83. 83 Rutgeerts, P.J., et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 62 (2013), 1122–1130.
84. 84 Vermeire, S., et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 384 (2014), 309–318.
85. 85 Tew, G.W., et al. Association between response to etrolizumab and expression of integrin αE and granzyme A in colon biopsies of patients with ulcerative colitis. Gastroenterology 150 (2016), 477–487.
86. 86 Vermeire, S., et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 60 (2011), 1068–1075.
87. 87 Sandborn, W.J., et al. Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease: results of the OPERA Study. Gastroenterology, 148(Suppl. 1), 2015, S162.
88. 88 Reinisch, W., et al. A randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 (PF) in patients with moderate to severe ulcerative colitis: results of the TURANDOT Study. Gastroenterology, 148(Suppl. 1), 2015, S1193.
89. 89 Sanchez, T., Hla, T., Structural and functional characteristics of S1P receptors. J. Cell Biochem. 92 (2004), 913–922.
90. 90 Degagne, E., Saba, J.D., S1pping fire: sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer. Clin. Exp. Gastroenterol. 7 (2014), 205–214.
91. 91 Sandborn, W.J., et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N. Engl. J Med. 374 (2016), 1754–1762.
92. 92 Hazlewood, G.S., et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology 148 (2015), 344–354.
93. 93 Khamsi, R., A gut feeling about immunity. Nat. Med. 21 (2015), 674–676.
94. 94 Mosli, M.H., et al. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am. J Gastroenterol. 109 (2014), 994–1004.
95. 95 Kingsley, M.J., Abreu, M.T., A personalized approach to managing inflammatory bowel disease. Gastroenterol Hepatol. 12 (2016), 308–315.
96. 96 Karmiris, K., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 137 (2009), 1628–1640.
97. 97 Seow, C.H., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 59 (2010), 49–54.
98. 98 Nanda, K.S., et al. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 108 (2013), 40–47.
99. 99 Steenholdt, C., et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 63 (2014), 919–927.
100. 100 Pritchard, D., et al. What contributes most to high health care costs? Health care spending in high resource patients. J Manag. Care Spec. Pharm. 22 (2016), 102–109.
101. 101 Steenholdt, C., et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm. Bowel. Dis. 22 (2016), 1999–2015.
102. 102 Burke, J.P., et al. Fibrogenesis in Crohn's disease. Am. J. Gastroenterol. 102 (2007), 439–448.